1. 💔🩸⚖️ Aspirin, Anticoagulants & Harm: Rethinking Dual Therapy in Stable CAD

💊🫀 Aspirin in the Crosshairs? The AQUATIC Trial (NEJM, Aug 2025) raises sharp questions on dual-pathway therapy in chronic coronary syndrome (CCS) patients already on long-term anticoagulation. 📉 Adding aspirin led to: • ↑ Ischemic events (HR 1.53; P=0.02) • ↑ Mortality (HR 1.72; P=0.01) • ↑ Major bleeding (HR 3.35; P) 🧠 Takeaway: More isn't always better. In high-risk CCS, aspirin may harm more than help. 📚 Read: https://www.nejm.org/doi/full/10.1056/NEJMoa2507532 #Cardiology #Antiplatelet #NEJM #PrecisionMedicine #AQUATICTrial